29th Mar 2016 13:55
BLOCK LISTING SIX MONTHLY RETURN
VERNALIS PLC (the "Company")
29 March 2016
Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:
Name of applicant: | Vernalis plc | |||||||||||
Name of scheme(s): | 2007 Long Term Incentive Scheme ("LTIP") and the Savings Related Share Option Plan 2003 ("SAYE") | |||||||||||
Period of return (from / to): | From: 25/Sept/2015 | To: 29/Mar/2016 | ||||||||||
Balance of unallotted securities under scheme(s) from previous return: | Total of 2,739,415 Ordinary 1p Shares, split: · Under LTIP = 1,101,069 Ordinary 1p Shares · Under SAYE = 1,638,346 Ordinary 1p Shares | |||||||||||
Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for): | Total of 1,189,296 Ordinary 1p Shares, split · Under LTIP = 1,189,296 Ordinary 1p Shares · Under SAYE = NIL Ordinary 1p Shares | |||||||||||
Less: Number of securities issued/allotted under scheme(s) during period: | Total of 1,685,393 Ordinary 1p Shares, split: · Under LTIP = 47,047 Ordinary 1p Shares · Under SAYE = 1,638,346 Ordinary 1p Shares | |||||||||||
Less: Number of securities forfeited under scheme(s) during period: | NIL | |||||||||||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | Total of 2,243,318 Ordinary 1p Shares, split: · Under LTIP = 2,243,318 Ordinary 1p Shares · Under SAYE = NIL Ordinary 1p Shares | |||||||||||
Number and class of securities originally admitted and the date of admission (including any additions): |
A block listing application for 1,189,296 Ordinary 1p Shares has been made on 29 March 2016 and admission is expected to take place on 1 April 2016. | |||||||||||
-- ends -
Enquiries:
Vernalis plc: | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer |
|
David Mackney, Chief Financial Officer
|
|
Canaccord Genuity Limited (Nominated Adviser): | +44 (0) 20 7523 8000 |
Dr Julian Feneley |
|
Henry Fitzgerald-O'Connor |
|
Emma Gabriel
|
|
Shore Capital (Joint Broker): | +44 (0) 20 7408 4090 |
Bidhi Bhoma |
|
Toby Gibbs
|
|
FTI Consulting: | +44 (0) 20 3727 1000 |
Ben Atwell |
|
Simon Conway |
|
Stephanie Cuthbert
|
|
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra® XR targeting the US prescription cough cold market; Moxatag®, a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adult and paediatric patients 12 years of age or older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, Taisho and Tris.
For further information about Vernalis, please visit www.vernalis.com.
Related Shares:
Vernalis PLC